JP2021532193A5 - - Google Patents
Info
- Publication number
- JP2021532193A5 JP2021532193A5 JP2021529250A JP2021529250A JP2021532193A5 JP 2021532193 A5 JP2021532193 A5 JP 2021532193A5 JP 2021529250 A JP2021529250 A JP 2021529250A JP 2021529250 A JP2021529250 A JP 2021529250A JP 2021532193 A5 JP2021532193 A5 JP 2021532193A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- solid dispersion
- leukemia
- composition according
- polymer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862714182P | 2018-08-03 | 2018-08-03 | |
| US62/714,182 | 2018-08-03 | ||
| PCT/US2019/044853 WO2020028778A1 (en) | 2018-08-03 | 2019-08-02 | Bioavailable oral dosage forms |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021532193A JP2021532193A (ja) | 2021-11-25 |
| JP2021532193A5 true JP2021532193A5 (https=) | 2022-10-07 |
Family
ID=67766269
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021529250A Pending JP2021532193A (ja) | 2018-08-03 | 2019-08-02 | 生物学的に利用可能な経口剤形 |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US20210205225A1 (https=) |
| EP (1) | EP3829544A1 (https=) |
| JP (1) | JP2021532193A (https=) |
| KR (1) | KR20210041589A (https=) |
| CN (1) | CN112752570A (https=) |
| AR (1) | AR115913A1 (https=) |
| AU (1) | AU2019316036A1 (https=) |
| BR (1) | BR112021001859A2 (https=) |
| CA (1) | CA3107737A1 (https=) |
| CL (1) | CL2021000271A1 (https=) |
| CO (1) | CO2021001979A2 (https=) |
| CR (1) | CR20210093A (https=) |
| EA (1) | EA202190429A1 (https=) |
| EC (1) | ECSP21011795A (https=) |
| IL (1) | IL280471A (https=) |
| MX (1) | MX2021001364A (https=) |
| NI (1) | NI202100006A (https=) |
| PE (1) | PE20211410A1 (https=) |
| PH (1) | PH12021550237A1 (https=) |
| SG (1) | SG11202100984VA (https=) |
| TN (1) | TN2021000021A1 (https=) |
| TW (1) | TW202019414A (https=) |
| WO (1) | WO2020028778A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX373926B (es) | 2009-05-27 | 2020-07-10 | Ptc Therapeutics Inc | Metodos para tratar cancer y estados no neoplasicos. |
| EP3664803A4 (en) | 2017-08-01 | 2021-05-05 | PTC Therapeutics, Inc. | DHODH INHIBITOR FOR USE IN THE TREATMENT OF HEMATOLOGICAL CANCERS |
| CN112028888B (zh) * | 2020-09-11 | 2021-08-20 | 中国药科大学 | 一种化合物及其制备方法和用途 |
| US20250186437A1 (en) | 2021-12-31 | 2025-06-12 | Ptc Therapeutics, Inc. | Carboline compounds and use thereof |
| US20220151938A1 (en) * | 2022-01-28 | 2022-05-19 | Ptc Therapeutics, Inc. | Tablet for use in treating huntington's disease and method of making the same |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050249799A1 (en) | 2004-03-03 | 2005-11-10 | Spherics, Inc. | Polymeric drug delivery system for hydrophobic drugs |
| US7767689B2 (en) | 2004-03-15 | 2010-08-03 | Ptc Therapeutics, Inc. | Carboline derivatives useful in the treatment of cancer |
| UA92317C2 (ru) | 2004-03-15 | 2010-10-25 | Пи-Ти-Си ТЕРАПЬЮТИКС, ИНК. | Производные карболина, пригодные для ингибирования развития кровеносных сосудов |
| US8076352B2 (en) | 2004-03-15 | 2011-12-13 | Ptc Therapeutics, Inc. | Administration of carboline derivatives useful in the treatment of cancer and other diseases |
| US8076353B2 (en) | 2004-03-15 | 2011-12-13 | Ptc Therapeutics, Inc. | Inhibition of VEGF translation |
| US20100158858A1 (en) | 2007-04-13 | 2010-06-24 | Liangxian Cao | Administration of carboline derivatives useful in the treatment of cancer and other diseases |
| DK2200588T3 (da) | 2007-09-25 | 2019-07-01 | Solubest Ltd | Sammensætninger, som omfatter lipofile aktive forbindelser, og fremgangsmåde til fremstilling deraf |
| WO2009100176A2 (en) * | 2008-02-07 | 2009-08-13 | Abbott Laboratories | Pharmaceutical dosage form for oral administration of tyrosine kinase inhibitor |
| MX373926B (es) * | 2009-05-27 | 2020-07-10 | Ptc Therapeutics Inc | Metodos para tratar cancer y estados no neoplasicos. |
| US20120202801A1 (en) * | 2009-05-27 | 2012-08-09 | Liangxian Cao | Methods for treating breast cancer |
| WO2017091373A1 (en) * | 2015-11-25 | 2017-06-01 | Patheon Development Services Inc. | Amorphous dispersion granules and oral dosage forms |
-
2019
- 2019-08-02 CA CA3107737A patent/CA3107737A1/en active Pending
- 2019-08-02 TN TNP/2021/000021A patent/TN2021000021A1/en unknown
- 2019-08-02 EP EP19759102.7A patent/EP3829544A1/en not_active Withdrawn
- 2019-08-02 US US17/264,940 patent/US20210205225A1/en not_active Abandoned
- 2019-08-02 KR KR1020217006355A patent/KR20210041589A/ko not_active Ceased
- 2019-08-02 SG SG11202100984VA patent/SG11202100984VA/en unknown
- 2019-08-02 CN CN201980065062.1A patent/CN112752570A/zh active Pending
- 2019-08-02 EA EA202190429A patent/EA202190429A1/ru unknown
- 2019-08-02 MX MX2021001364A patent/MX2021001364A/es unknown
- 2019-08-02 WO PCT/US2019/044853 patent/WO2020028778A1/en not_active Ceased
- 2019-08-02 JP JP2021529250A patent/JP2021532193A/ja active Pending
- 2019-08-02 PE PE2021000157A patent/PE20211410A1/es unknown
- 2019-08-02 AU AU2019316036A patent/AU2019316036A1/en not_active Abandoned
- 2019-08-02 CR CR20210093A patent/CR20210093A/es unknown
- 2019-08-02 BR BR112021001859-0A patent/BR112021001859A2/pt not_active IP Right Cessation
- 2019-08-05 AR ARP190102223A patent/AR115913A1/es not_active Application Discontinuation
- 2019-08-05 TW TW108127793A patent/TW202019414A/zh unknown
-
2021
- 2021-01-28 IL IL280471A patent/IL280471A/en unknown
- 2021-02-01 PH PH12021550237A patent/PH12021550237A1/en unknown
- 2021-02-02 CL CL2021000271A patent/CL2021000271A1/es unknown
- 2021-02-03 NI NI202100006A patent/NI202100006A/es unknown
- 2021-02-18 CO CONC2021/0001979A patent/CO2021001979A2/es unknown
- 2021-02-19 EC ECSENADI202111795A patent/ECSP21011795A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021532193A5 (https=) | ||
| KR101489401B1 (ko) | 약 염기성 약물과 유기산을 포함하는 약물 전달 시스템 | |
| CN110290781A (zh) | 胃肠特定部位控制释放的剂型 | |
| CN107260695A (zh) | 硝唑尼特的控制释放药物剂型 | |
| SK285300B6 (sk) | Farmaceutická formulácia obsahujúca množinu liekových podjednotiek a spôsob jej výroby | |
| JP2013533241A (ja) | 食物効果が減少した制御放出組成物 | |
| JP2022535893A5 (https=) | ||
| US11135159B2 (en) | Optimized high-dose mesalazine-containing tablet | |
| JP7652787B2 (ja) | ベンズイミダゾール誘導体化合物を含有する医薬組成物 | |
| WO2013132208A1 (en) | Pharmaceutical antiretroviral combinations comprising lamivudine, festinavir and nevirapine | |
| WO2021129735A1 (zh) | 一种固体制剂及其制备方法和用途 | |
| CN105338970A (zh) | 包含他达拉非和坦洛新的药物胶囊复合制剂 | |
| JP2023134691A (ja) | フペルジンの放出調節医薬組成物およびその使用方法 | |
| JP6902043B2 (ja) | フマル酸ジメチルを含む医薬ビーズ製剤 | |
| CN108012526A (zh) | 具有改进的生物利用度的含普仑司特固体制剂的组合物及其制备方法 | |
| EP3513784A1 (en) | Esomeprazole-containing complex capsule and preparation method therefor | |
| TWI651084B (zh) | 包含異菸鹼醯胺（ｉｓｏｎｉａｚｉｄ）顆粒及利福噴丁（ｒｉｆａｐｅｎｔｉｎｅ）顆粒之包衣錠劑型態的抗肺結核穩定醫藥組合物及其製備方法 | |
| US20080118554A1 (en) | Pharmaceutical compositions comprising a combination of piperidinoalkanol and decongestant | |
| CN101411702B (zh) | 盐酸奈福泮萘普生钠复方缓释制剂及其制备方法 | |
| JP2018123140A (ja) | 活性成分（ｉ）含有組成物及びその製造方法 | |
| KR101761983B1 (ko) | 구강내 속붕해 필름 조성물 및 그 제조방법 | |
| CN1863512A (zh) | 控释药物组合物及其制备方法 | |
| JP2023510965A5 (https=) | ||
| CN101909625A (zh) | 新型抗逆转录病毒组合 | |
| WO2015197535A1 (en) | Modified release pharmaceutical compositions of sofosbuvir and ribavirin |